

## FINAL PLACEMENT CONCLUDES ENTITLEMENT OFFER

*\$500,000 completes the targeted \$4,500,000 Entitlement Offer*

**Adelaide, Australia, 8 December 2023:** Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to advise that it has completed the final placement under the Company's partly underwritten Renounceable Pro-Rata Entitlement Offer and Shortfall Offer (**Entitlement Offer**), bringing the total raised to the targeted maximum of \$4,500,000.

### Highlights:

- **Entitlement Offer target of \$4.5 million achieved with the final placement of \$500,000**
- **Additional funds to be focussed on accelerating market development for APAS® PharmaQC**
- **APAS® PharmaQC remains on track for completion in the first quarter of CY2024**

The Company has completed the final placement of \$500,000 under the terms of the Entitlement Offer announced on 13 October 2023, bringing total raised to the targeted \$4,500,000. The placement was taken up by strategic investors that were part of the cornerstone sub underwriters to the Entitlement Offer. The Entitlement Offer was part of a wider financial restructure including the refinancing of the remaining \$1.7 million loan from the South Australian Government and the termination of a Share Placement Facility which removed market overhang (refer ASX Announcement 20 November 2023).

The Company had previously advised shareholders of this remaining \$500,000 available for placement within three months of the closing of the Entitlement Offer. Funds raised will allow the Company to accelerate market development activities for APAS® PharmaQC.

Rebecca Wilson, Chair of the Board said:

*"We are pleased to finalise the full placement of \$4,500,000 announced to the market in October 2023. The Company has established a revised strategy to focus on the pharmaceutical market and is now capitalised to execute against this strategy. I look forward to providing further updates regarding the pharmaceutical market in early 2024."*

Refer to the Prospectus for full details of the Entitlement Offer:

<https://www.lbtinnovations.com/wp-content/uploads/Prospectus.pdf>

Approved for release by the Chair of the LBT Board.

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Channel partners for the sale and distribution of the APAS® Independence are in place for the United States (Thermo Fisher Scientific, Inc; Exclusive Distributor) and selected countries in Europe (Beckman Coulter, Inc; Marketing Agent).

### INVESTOR ENQUIRIES

<b>LBT Innovations</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>